Volume 14 - Issue 5 - May, 2002
Nonhyperparathyroid Wound Calcifications: Two Case Presentations and Literature Review
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 4841 reads
Introduction
Subcutaneous calcification has been well described in the medical literature as a complication of chronic venous insufficiency.1 Other occurrences of such calcifications have been noted due to causes that are not well understood. Regardless of the etiology, the presence of calcium deposits in soft tissues may lead to chronic wounds that do not respond to conservative local wound care.2 For healing to occur it is well established that the solid calcific deposits and surrounding devitalized tissue must be removed from the wound sites.3 The mechanism for nonhe
A Cost Analysis of a Living Skin Equivalent in the Treatment of Diabetic Foot Ulcers
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 3637 reads
Introduction
It is estimated that 15 percent of patients with diabetes will develop foot ulcers and that 15 to 20 percent of those will progress to lower-extremity amputation.1,2 Indeed, it has been reported that foot ulcers precede 85 percent of all nontraumatic, lower-extremity amputations.3 The cost of treating diabetic foot ulcers (DFUs) is reported to range between $4,000.00 to $8,000.00 per ulcer episode and almost $28,000.00 over the first two years after diagnosis.1,3 The attributable cost of amputations is estimated at between $20,000.00 to $60,000.00.2,3
PART I: A New Biomaterial Derived from Small Intestine Submucosa and Developed into a Wound Matrix Device
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 3961 reads
Introduction
Biomaterials have become critical components in the development of effective new medical therapies for wound care. As limitations of previous generations of biologically derived materials are overcome, many new and impressive applications for biomaterials are being examined. A new biomaterial was first discovered in 1987 at Purdue University (West Lafayette, Indiana) when researchers were evaluating various biological materials as blood conduits. This biomaterial was derived from small intestine submucosa (SIS). The SIS biomaterial has since been developed into several medical
PART II: A New Biomaterial Derived from Small Intestine Submucosa and Developed into a Wound Matrix Device
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 2553 reads
Initial Clinical Experience with the Wound Matrix
WMD, developed from SIS biomaterial, was subjected to biocompatibility testing prior to its use in a clinical setting. Following completion of standard in-vitro and in-vivo biocompatibility testing, WMD was cleared by the Food and Drug Administration (FDA) for the intended use of management of partial-thickness wounds.
WMD was evaluated in a pilot study for effectiveness in treating partial-thickness skin wounds. The dressings used in this study were supplied as 7cm x 10cm sheets having a thickness of approximately 0.15mm. The sterile dr
WOUNDS May
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 987 reads
New Episcan Imaging Ultrasound from ExcellaDerm Corporation
ExcellaDerm Corporation is debuting a revolutionary portable ultrasound skin imaging system. This system has significantly advanced skin-imaging procedures that can show irregularities and growths before they appear on the surface. Along with its other products, the Episcan will allow ExcellaDerm to offer the most comprehensive line of skin care solutions available.
The Episcan images the skin at high resolution and with great clarity up to 30 millimeters (1.5 inches) of subdermal tissue. This will enable physicians to visualize a
WOUNDS May
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 1251 reads
Stem Cell Research Foundation’s First Grant Awarded to John D. Gearhart
The Stem Cell Research Foundation (SCRF), a program of the American Cell Therapy Research Foundation, has awarded its first research grant to John D. Gearhart, PhD, of the Johns Hopkins School of Medicine in Baltimore, Maryland. The foundation was established in 2000 to help fund cutting-edge research in the new science. Dr. Gearhart and his coinvestigator, Michael J. Shamblott, PhD, also of Johns Hopkins, will be working with human pluripotent stem cells in an attempt to develop a hardier, more useful stem cell line
_sm.jpg)
